Jury rules Prempro caused woman’s breast cancer

Share this article:
A Philadelphia jury found on Tuesday that Wyeth’s hormone replacement therapy Prempro was the cause of a woman’s breast cancer and awarded her and her husband damages of $3 million. Wyeth said it plans to appeal the decision. “We respectfully disagree that there is any scientific basis to support the jury’s finding of a causal link between Wyeth’s hormone therapies and the plaintiff’s breast cancer,” said Barbara Binis, an attorney representing Wyeth in the case. A previous Philadelphia jury also found in favor of the plaintiff, Jennie Nelson in October. However the judge threw out that verdict and declared a mistrial, leading to the trial that concluded yesterday. The original jury had awarded Nelson and her husband $1.5 million in compensatory damages. This time Nelson was awarded $2.4 million and her husband $600,000. The reason for the mistrial was not disclosed however there has been speculation since that it may have been overturned as a result of juror misconduct. Wyeth is facing approximately 5,000 lawsuits over its hormone replacement therapies. The drugs remain on the market despite a major government-sponsored study that found using them for five years or more can increase the risk of breast cancer.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...